The strategies used for treatment of experimental autoimmune neuritis (EAN): A beneficial effect of glatiramer acetate administered intraperitoneally

Clinical Reviews in Allergy and Immunology

Volumn 42, Issue 2, 2012, Pages 181-188

  Aronovich, Ramona ^a   Katzav, Aviva ^a   Chapman, Joab ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Experimental autoimmune neuritis; Glatiramer acetate; Guillain Barr syndrome

Indexed keywords

GLATIRAMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; AUTOIMMUNE DISEASE; AUTOIMMUNE NEURITIS; BRAIN ELECTROPHYSIOLOGY; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MULTIPLE SCLEROSIS; NERVE CONDUCTION; NEURITIS; NEUROPHYSIOLOGY; NONHUMAN; RAT; REVIEW;

ANIMALS; AUTOANTIGENS; CELL PROLIFERATION; CELLS, CULTURED; DISEASE PROGRESSION; FEMALE; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOMODULATION; INJECTIONS, INTRAPERITONEAL; LYMPHOCYTES; MYELIN SHEATH; NEURITIS, AUTOIMMUNE, EXPERIMENTAL; PEPTIDES; RATS; RATS, INBRED LEW;

EID: 84860698643     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-010-8246-7     Document Type: Review

References (64)

1. Arnon R, Teitelbaum D, Sela M (1989) Suppression of experimental allergic encephalomyelitis by COP1-relevance to multiple sclerosis. Isr J Med Sci 25:686-689 (Pubitemid 20032129)
2. Teitelbaum D, Arnon R, Sela M (1997) Copolymer 1: from basic research to clinical application. Cell Mol Life Sci 53:24-28 (Pubitemid 27379370)
3. Soffer D, Feldman S, Alter M (1978) Epidemiology of Guillain-Barre syndrome. Neurology 28:686-690 (Pubitemid 8364274)
4. Shoenfeld Y, George J, Peter JB (1996) Guillain-Barre as an autoimmune disease. Int Arch Allergy Immunol 109:318-326 (Pubitemid 26082838)
5. Israeli E, Agmon-Levin N, Blank M, Chapman J, Shoenfeld Y (2010) Guillain-Barre Syndrome-A Classical Autoimmune Disease Triggered by Infection or Vaccination. Clin Rev Allergy Immunol doi:10.1007/s12016-010-8213-3
6. Kadlubowski M, Hughes RA (1979) Identification of the neuritogen for experimental allergic neuritis. Nature 277:140-141 (Pubitemid 9093806)
7. Shin HC, McFarlane EF, Pollard JD, Watson EG (1989) Induction of experimental allergic neuritis with synthetic peptides from myelin P2 protein. Neurosci Lett 102:309-312 (Pubitemid 19179809)
8. Waksman BH, Adams RD (1955) Allergic neuritis: an experi-mental disease of rabbits induced by the injection of peripheral nervous tissue and adjuvants. J Exp Med 102:213-236
9. Mendell JR, Kissel JT, Kennedy MS, Sahenk Z, Grinvalsky HT, Pittman GL, Kyler RS, Roelofs RI, Whitaker JN, Bertorini TE (1985) Plasma exchange and prednisone in Guillain-Barre syndrome: a controlled randomized trial. Neurology 35:1551-1555 (Pubitemid 16248661)
10. McDaneld LM, Fields JD, Bourdette DN, Bhardwaj A (2010) Immunomodulatory therapies in neurologic critical care. Neurocrit Care 12:132-143
11. Pithadia AB, Kakadia N (2010) Guillain-Barre syndrome (GBS). Pharmacol Rep 62:220-232
12. Vucic S, Kiernan MC, Cornblath DR (2009) Guillain-Barre syndrome: an update. J Clin Neurosci 16:733-741
13. Harel M, Shoenfeld Y (2005) Intravenous immunoglobulin and Guillain-Barre syndrome. Clin Rev Allergy Immunol 29:281-287
14. Kafri M, Kloog Y, Korczyn AD, Ferdman-Aronovich R, Drory V, Katzav A, Wirguin I, Chapman J (2005) Inhibition of Ras attenuates the course of experimental autoimmune neuritis. J Neuroimmunol 168:46-55 (Pubitemid 41398186)
15. Kafri M, Drory VE, Wang N, Rabinowitz R, Korczyn AD, Chapman J (2002) Assessment ofexperimental autoimmune neuritis in the rat by electrophysiology of the tail nerve. Muscle Nerve 25:51-57 (Pubitemid 34019735)
16. Maurer M, Toyka KV, Gold R (2002) Cellular immunity in inflammatory autoimmune neuropathies. Rev Neurol Paris 158:S7-S15
17. Zhang ZY, Zhang Z, Schluesener HJ (2010) MS-275, an histone deacetylase inhibitor, reduces the inflammatory reaction in rat experimental autoimmune neuritis. Neuroscience 169:370-377
18. Zhang Z, Zhang ZY, Schluesener HJ (2009) Compound A, a plant origin ligand of glucocorticoid receptors, increases regulatory T cells and M2 macrophages to attenuate experimental autoimmune neuritis with reduced side effects. J Immunol 183:3081-3091
19. TanXD, Dou YC, Shi CW, Duan RS, Sun RP (2009) Administration of dehydroepiandrosterone ameliorates experimental autoimmune neuritis in Lewis rats. J Neuroimmunol 207:39-44
20. Zhang Z, Zhang ZY, Fauser U, Schluesener HJ (2008) Valproic acid attenuates inflammation in experimental autoimmune neuritis. Cell Mol Life Sci 65:4055-4065
21. Zhang ZY, Zhang Z, Fauser U, Schluesener HJ (2009) Improved outcome of EAN, an animal model of GBS, through amelioration ofperipheral and central inflammation by minocycline. J Cell Mol Med 13:341-351
22. Sarkey JP, Richards MP, Stubbs EB Jr (2007) Lovastatin attenuates nerve injury in an animal model of Guillain-Barre syndrome. JNeurochem 100:1265-1277
23. Bao L, Lindgren JU, Zhu Y, Ljunggren HG, Zhu J (2003) Exogenous soluble tumor necrosis factor receptor type I amelio-rates murine experimental autoimmune neuritis. Neurobiol Dis 12:73-81 (Pubitemid 36259969)
24. Taylor JM, Pollard JD (2007) Soluble TNFR1 inhibits the develop-ment of experimental autoimmune neuritis by modulating blood-nerve-barrier permeability and inflammation. J Neuroimmunol 183:118-124 (Pubitemid 46204916)
25. Castro FR, Farias AS, Proenca PL, de La Hoz C, Langone F, Oliveira EC, Toyama MH, Marangoni S, Santos LM (2007) The effect of treatment with crotapotin on the evolution of experimen-tal autoimmune neuritis induced in Lewis rats. Toxicon 49:299-305 (Pubitemid 46185515)
26. Nicoletti F, Creange A, Orlikowski D, Bolgert F, Mangano K, Metz C, Di Marco R, Al Abed Y (2005) Macrophage migration inhibitory factor (MIF) seems crucially involved in Guillain-Barre syndrome and experimental allergic neuritis. J Neuroimmunol 168:168-174 (Pubitemid 41396415)
27. Schmidt J, Elflein K, Stienekemeier M, Rodriguez-Palmero M, Schneider C, Toyka KV, Gold R, Hunig T (2003) Treatment and prevention of experimental autoimmune neuritis with super-agonistic CD28-specific monoclonal antibodies. J Neuroimmunol 140:143-152 (Pubitemid 36836099)
28. Miyamoto K, Oka N, Kawasaki T, Miyake S, Yamamura T, Akiguchi I (2002) New cyclooxygenase-2 inhibitors for treatment ofexperimental autoimmune neuritis. Muscle Nerve 25:280-282 (Pubitemid 34117077)
29. Di Marco R, Khademi M, Wallstrom E, Muhallab S, Nicoletti F, Olsson T (1999) Amelioration ofexperimental allergic neuritis by sodium fusidate (fusidin): suppression of IFN-gamma and TNF-alpha and enhancement ofIL-10. J Autoimmun 13:187-195 (Pubitemid 29436133)
30. Hartung HP, Schafer B, Fierz W, Heininger K, Toyka KV (1987) Ciclosporin A prevents P2 T cell line-mediated experimental autoimmune neuritis (AT-EAN) in rat. Neurosci Lett 83:195-200 (Pubitemid 18001450)
31. Bai XF, Zhu J, Zhang GX, Kaponides G, Hojeberg B, van der Meide PH, Link H (1997) IL-10 suppresses experimental autoimmune neuritis and down-regulates TH1-type immune responses. Clin Immunol Immunopathol 83:117-126 (Pubitemid 27195931)
32. Jung S, Toyka K, Hartung HP (1996) T cell directed immuno-therapy of inflammatory demyelination in the peripheral nervous system. Potent suppression of the effector phase of experimental autoimmune neuritis by anti-CD2 antibodies. Brain 119(Pt4):1079-1090 (Pubitemid 26300710)
33. Archelos JJ, Maurer M, Jung S, Toyka KV, Hartung HP (1993) Suppression of experimental allergic neuritis by an antibody to the intracellular adhesion molecule ICAM-1. Brain 116(Pt 5):1043-1058 (Pubitemid 23329880)
34. Usuki S, Taguchi K, Thompson SA, Chapman PB, Yu RK (2010) Novel anti-idiotype antibody therapy for lipooligosaccharide-induced experimental autoimmune neuritis: use relevant to Guillain-Barre syndrome. J Neurosci Res 88:1651-1663
35. Jung S, Gaupp S, Korn T, Kollner G, Hartung HP, Toyka KV (2004) Biphasic form of experimental autoimmune neuritis in dark Agouti rats and its oral therapy by antigen-specific tolerization. J Neurosci Res 75:524-535 (Pubitemid 38165360)
36. Zou LP, Ma DH, Levi M, Wahren B, Wei L, Mix E, van der Meide PH, Link H, Zhu J (1999) Antigen-specific immunosup-pression: nasal tolerance to P0 protein peptides for the prevention and treatment ofexperimental autoimmune neuritis in Lewis rats. J Neuroimmunol 94:109-121 (Pubitemid 29071250)
37. Offenhausser M, Herr AS, Hartkamp J, Wauben M, Magnus T, Grauer O, Seubert S, Weishaupt A, Toyka KV, Gold R, Troppmair J (2002) Truncation of the neuritogenic peptide bP2(60-70) results in the generation of altered peptide ligands with the potential to interfere with T cell activation. J Neuroimmunol 129:97-105 (Pubitemid 34874914)
38. Dati G, Quattrini A, Bernasconi L, Malaguti MC, Antonsson B, Nicoletti F, Alliod C, Di Marco R, Sagot Y, Vitte PA, Hiver A, Greco B, Roach A, Zaratin PF (2007) Beneficial effects of r-h-CLU on disease severity in different animal models of peripheral neuropathies. JNeuroimmunol 190:8-17 (Pubitemid 47625599)
39. Bechtold DA, Yue X, Evans RM, Davies M, Gregson NA, Smith KJ (2005) Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent flecainide. Brain 128:18-28 (Pubitemid 40070516)
40. The Guillain-Barre syndrome Study Group (1985) Plasmapheresis and acute Guillain-Barre syndrome. Neurology 35:1096-1104
41. Enders U, Toyka KV, Hartung HP, Gold R (1997) Failure of intravenous immunoglobulin (IVIg) therapy in experimental autoim-mune neuritis (EAN) of the Lewis rat J Neuroimmunol76:112-116 (Pubitemid 27272636)
42. Gabriel CM, Gregson NA, Redford EJ, Davies M, Smith KJ, Hughes RA (1997) Human immunoglobulin ameliorates rat experimental autoimmune neuritis. Brain 120(Pt 9):1533-1540 (Pubitemid 27389221)
43. Jia J, Jia J, Pollock M (2000) Treatment of rats with experimental allergic neuritis using high dose immunoglobulin. Chin Med J (Engl) 113:1096-1099
44. Lin HH, Spies JM, Lu JL, Pollard JD (2007) Effective treatment ofexperimental autoimmune neuritis with human immunoglobulin. J Neurol Sci 256:61-67 (Pubitemid 46560627)
45. Lin HH, Wang MX, Spies JM, Pollard JD (2007) Effective treatment of experimental autoimmune neuritis with Fc fragment of human immunoglobulin. J Neuroimmunol 186:133-140 (Pubitemid 46770869)
46. Miyagi F, Horiuchi H, Nagata I, Kitahara S, Kiyoki M, Komoriya K, Yuki N (1997) Fc portion of intravenous immunoglobulin suppresses the induction of experimental allergic neuritis. J Neuroimmunol 78:127-131 (Pubitemid 27394433)
47. Hughes RA, Kadlubowski M, Hufschmidt A (1981) Treatment of acute inflammatory polyneuropathy Ann Neurol9(Suppl):125-133 (Pubitemid 11120645)
48. Zhu J, Bai XF, Hedlund G, Bjork J, Bakhiet M, Van Der Meide PH, Link H (1999) Linomide suppresses experimental autoim-mune neuritis in Lewis rats by inhibiting myelin antigen-reactive T and B cell responses. Clin Exp Immunol 115:56-63 (Pubitemid 29030363)
49. Zou LP, Abbas N, Volkmann I, Nennesmo I, Levi M, Wahren B, Winblad B, Hedlund G, Zhu J (2002) Suppression ofexperimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology 42:731-739 (Pubitemid 34457755)
50. Zou LP, Ma DH, Wei L, van der Meide PH, Mix E, Zhu J (1999) IFN-beta suppresses experimental autoimmune neuritis in Lewis rats by inhibiting the migration of inflammatory cells into peripheral nervous tissue. J Neurosci Res 56:123-130 (Pubitemid 29201051)
51. Yu S, Chen Z, Mix E, Zhu SW, Winblad B, Ljunggren HG, Zhu J (2002) Neutralizing antibodies to IL-18 ameliorate experimental autoimmune neuritis by counter-regulation of autoreactive Th1 responses to peripheral myelin antigen. J Neuropathol Exp Neurol 61:614-622 (Pubitemid 34721466)
52. Zhang Z, Zhang ZY, Fauser U, Schluesener HJ (2008) FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves. Exp Neurol 210:681-690
53. Zhang ZY, Zhang Z, Zug C, Nuesslein-Hildesheim B, Leppert D, Schluesener HJ (2009) AUY954, a selective S1P(1) modulator, prevents experimental autoimmune neuritis. J Neuroimmunol 216:59-65
54. O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T (2009) 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 8:889-897
55. McDermott JR, Keith AB (1980) Antigen-induced suppression of experimental allergic neuritis in the guinea pig. J Neurol Sci 46:137-143 (Pubitemid 10153820)
56. Kadlubowski M, Hughes RA, Gregson NA (1980) Experimental allergic neuritis in the Lewis rat: characterization of the activity of peripheral myelin and its major basic protein, P2. Brain Res 184:439-454 (Pubitemid 10187606)
57. Hoffman PM, Powers JM, Weise MJ, Brostoff SW (1980) Experimental allergic neuritis. I. Rat strain differences in the response to bovine myelin antigens. Brain Res 195:355-362 (Pubitemid 10090554)
58. Aharoni R, Eilam R, Stock A, Vainshtein A, Shezen E, Gal H, Friedman N, Arnon R (2010) Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE. J Neuroimmunol 225:100-111
59. Aharoni R, Teitelbaum D, Sela M, Arnon R (1997) Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalo-myelitis. Proc Natl Acad Sci USA 94:10821-10826 (Pubitemid 27430819)
60. Begum-Haque S, Sharma A, Kasper IR, Foureau DM, Mielcarz DW, Haque A, Kasper LH (2008) Downregulation ofIL-17 and IL-6 in the central nervous system by glatiramer acetate in experimental autoimmune encephalomyelitis. J Neuroimmunol 204:58-65
61. Laura M, Gregson NA, Curmi Y, Hughes RA (2002) Efficacy of leukemia inhibitory factor in experimental autoimmune neuritis. J Neuroimmunol 133:56-59 (Pubitemid 35346728)
62. Yu S, Zhu Y Chen Z, Alheim M, Ljungberg A, Zhu J (2002) Initiation and development of experimental autoimmune neuritis in Lewis rats is independent of the cytotoxic capacity of NKR-P1A+cells. J Neurosci Res 67:823-828 (Pubitemid 34226295)
63. Stienekemeier M, Falk K, Rotzschke O, Weishaupt A, Schneider C, Toyka KV, Gold R, Strominger JL (2001) Vaccination, prevention, and treatment of experimental autoimmune neuritis (EAN) by an oligomerized T cell epitope. Proc Natl Acad Sci USA 98:13872-13877 (Pubitemid 33115991)
64. Felts PA, Smith KJ, Gregson NA, Hughes RA (2002) Brain-derived neurotrophic factor in experimental autoimmune neuritis. J Neuro-immunol 124:62-69 (Pubitemid 34212011)